17
Participants
Start Date
April 30, 2006
Primary Completion Date
October 31, 2008
Study Completion Date
October 31, 2008
gemcitabine hydrochloride
1000 mg/m2 given intravenously at a FDR of 10 mg/m2/min on Days 3 and 10, every 21 days.
imatinib mesylate
400 mg/day orally, given Days 1-5 and 8-12 every 21 days
Cancer Institute of New Jersey at Hamilton, Hamilton
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick
Saint Peter's University Hospital, New Brunswick
Collaborators (1)
National Cancer Institute (NCI)
NIH
Novartis
INDUSTRY
Rutgers, The State University of New Jersey
OTHER